Literature DB >> 8398895

Expression of TRK-T1 oncogene induces differentiation of PC12 cells.

A Greco1, R Orlandi, C Mariani, C Miranda, M G Borrello, A Cattaneo, S Pagliardini, M A Pierotti.   

Abstract

The TRK-T1 oncogene, isolated from a human thyroid carcinoma, represents a rearranged form of the high affinity nerve growth factor (NGF) receptor encoded by the NTRK1 gene; it is created by an intrachromosomal rearrangement fusing the NTRK1 tyrosine kinase domain to the 5' portion of the TPR gene. We have investigated the effect of the TRK-T1 oncogene in PC12 cells, a model system for studying neuronal differentiation and the mechanism of action of NGF. Here, we report that, in PC12 cells, the TRK-T1 oncogene has a differentiating effect that resembles that of NGF and requires the phosphorylation of the oncoprotein. Our results are consistent with the hypothesis that TRK-T1, as well as the original TRK oncogene, induces PC12 differentiation by mimicking the action of NGF bound to its receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398895

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  8 in total

Review 1.  Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas.

Authors:  M A Pierotti; I Bongarzone; M G Borrello; C Mariani; C Miranda; G Sozzi; A Greco
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

Review 2.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

3.  A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.

Authors:  D Califano; A D'Alessio; G L Colucci-D'Amato; G De Vita; C Monaco; G Santelli; P P Di Fiore; G Vecchio; A Fusco; M Santoro; V de Franciscis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

4.  Role of STAT3 in in vitro transformation triggered by TRK oncogenes.

Authors:  Claudia Miranda; Tiziana Fumagalli; Maria Chiara Anania; Maria Grazia Vizioli; Sonia Pagliardini; Marco A Pierotti; Angela Greco
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

5.  Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure.

Authors:  A H Fischer; J A Bond; P Taysavang; O E Battles; D Wynford-Thomas
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

6.  The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.

Authors:  A Greco; C Mariani; C Miranda; A Lupas; S Pagliardini; M Pomati; M A Pierotti
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

7.  Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.

Authors:  Valentina Cirello; Valentina Vaira; Elisa Stellaria Grassi; Valeria Vezzoli; Dario Ricca; Carla Colombo; Silvano Bosari; Leonardo Vicentini; Luca Persani; Stefano Ferrero; Laura Fugazzola
Journal:  Oncotarget       Date:  2017-02-07

8.  MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay.

Authors:  Chiara Pesenti; Marina Muzza; Carla Colombo; Maria Carla Proverbio; Claudia Farè; Stefano Ferrero; Monica Miozzo; Laura Fugazzola; Silvia Tabano
Journal:  Endocrine       Date:  2017-12-06       Impact factor: 3.633

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.